Cosmetic surgeons try to correct 'Ozempic face' for weight-loss drug users
Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the ...
Drug Store News1d
FDA approves new indication for Novo Nordisk’s Ozempic
Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...
infectiousdiseaseadvisor.com2d
Ozempic Approval Expanded to Include T2D Patients With Chronic Kidney Disease
The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.
Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)
Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.
Patients who took Ozempic 2.0 in clinical trial reveal its staggering results... and terrifying side effects
Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.
Will This New GLP-1 Drug be More Powerful Than Ozempic?
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Ozempic crackdown: What you need to know about the new rules
Around half a million Britons are now thought to be using the medication, which can help them lose up to 20 per cent of their ...
Hosted on MSN4d
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...
This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy?
A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an ...